Rockwell Medical (NASDAQ: RMTI) is one of 19 public companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Rockwell Medical to related companies based on the strength of its profitability, valuation, earnings, analyst recommendations, dividends, risk and institutional ownership.

Risk and Volatility

Rockwell Medical has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500. Comparatively, Rockwell Medical’s rivals have a beta of 0.85, suggesting that their average stock price is 15% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Rockwell Medical and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rockwell Medical 1 0 1 1 2.67
Rockwell Medical Competitors 63 294 943 27 2.70

Rockwell Medical currently has a consensus target price of $9.33, indicating a potential upside of 18.90%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 16.92%. Given Rockwell Medical’s higher probable upside, equities analysts plainly believe Rockwell Medical is more favorable than its rivals.

Earnings and Valuation

This table compares Rockwell Medical and its rivals revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Rockwell Medical $54.04 million -$21.07 million -18.69
Rockwell Medical Competitors $2.57 billion $977.16 million 1.06

Rockwell Medical’s rivals have higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Rockwell Medical and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rockwell Medical -39.68% -42.22% -27.15%
Rockwell Medical Competitors -538.85% -41.85% -24.81%

Institutional & Insider Ownership

21.4% of Rockwell Medical shares are held by institutional investors. Comparatively, 66.4% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 15.9% of Rockwell Medical shares are held by insiders. Comparatively, 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Rockwell Medical rivals beat Rockwell Medical on 7 of the 12 factors compared.

About Rockwell Medical

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company’s drug products include Triferic (ferric pyrophosphate citrate) and Calcitriol (Active Vitamin D) Injection. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Calcitriol (active vitamin D) injection is indicated for treatment of secondary hyperparathyroidism in dialysis patients.

Receive News & Stock Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related stocks with our FREE daily email newsletter.